Clinical Trial: Microbiota and Immune SignatureS of Graves' Disease and Orbitopathy

U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07870161) titled 'Microbiota and Immune SignatureS of Graves' Disease and Orbitopathy' on Oct. 06.

Brief Summary: Graves' disease (GD) is the commonest cause of hyperthyroidism, characterised by anti-thyrotropin receptor autoantibodies (TRAb) persistently stimulating the thyroid gland. Around 30-50% GD patients also develop Graves' orbitopathy (GO), an orbital inflammation causing disfigurement and visual problems; moderate-to-severe forms represent 5% of GO cases and are associated with high risk of sight loss. Some risk factors for GO have been identified (i.e. smoking, stress, high TRAb titres, severe hyperthyroidism) and predictive models for dis...